Neogap strengthens its board with two new members
Neogap Therapeutics AB, developing individualised immunotherapy for cancer treatment, strengthens the board with two new members. Anna Kälvemark and Steve Glavas both have experience in transforming start-ups into successful companies and contribute with cutting-edge expertise in regulatory activities and commercialisation of life science companies.At Neogap Therapeutics' annual general meeting on May 20, Anna Kälvemark and Steve Glavas were elected new board members. "We would like to extend a warm welcome to Anna Kälvemark and Steve Glavas to Neogap's board. They are an ideal